Scholar Rock Holding Corp

Listed Company

SRRKCIK 0001727196NasdaqNon-AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-377.94M

Total Assets

$404.27M

Equity

$245.49M

Shares Out

114.88M

Op. Cash Flow

$-300.04M

Business

Scholar Rock Holding Corp is a late-stage biopharmaceutical company that discovers, develops and aims to deliver monoclonal antibody medicines that selectively target latent precursor forms of protein growth factors to modulate signaling in disease microenvironments. Its main product candidates include apitegromab (anti-myostatin for SMA), SRK-181 (latent TGFβ1 inhibitor for CPI-resistant cancers), SRK-439 (anti-myostatin for cardiometabolic disorders), SRK-373 (matrix-selective TGFβ1 inhibitor), SRK-256 (RGMc/hemojuvelin inhibitor) and earlier discovery programs. Key business activities comprise a proprietary structural-biology‑driven discovery platform, clinical development and strategic collaborations and licensing. The company conducts global clinical trials and regulatory interactions in the U.S. and Europe and intends commercial distribution through standard pharmaceutical channels following approvals.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	208	185	122	124	108
General and administrative	176	68	49	43	40
Total operating expenses	385	252	171	168	149
Loss from operations	−385	−252	−171	−134	−130
Interest income	14	13	—	—	—
Interest expense	−7	−7	—	—	—
Other expense, net	−301,000	−85,000	—	—	—
Total other income (expense), net	7	6	6	−132,000	−2
Net loss	−378	−246	−166	−135	−132
Net loss per share, basic (in dollars per share)	−3.29	−2.47	−1.99	−2.26	−3.59
Net loss per share, diluted (in dollars per share)	−3.29	−2.47	−1.99	−2.26	−3.59
Weighted average common shares outstanding, basic (in shares)	115	100	83	60	37
Weighted average common shares outstanding, diluted (in shares)	115	100	83	60	37
Unrealized gain (loss) on marketable securities	−64,000	68,000	976,000	−849,000	−33,000
Foreign currency translation adjustments	−2,000	—	—	—	—
Total other comprehensive income (loss)	−66,000	68,000	976,000	−849,000	−33,000
Comprehensive loss	−378	−246	−165	−135	−132

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	324	178	102	103	213
Marketable securities	44	259	178	212	40
Prepaid expenses and other current assets	18	14	8	13	12
Total current assets	385	451	288	328	265
Property and equipment, net	2	3	5	7	10
Operating lease right-of-use asset	10	16	11	19	25
Restricted cash	4	2	2	2	2
Other long-term assets	3	3	4	2	2
Total assets	404	475	311	358	304
Accounts payable	10	10	3	4	4
Accrued expenses	40	31	20	24	17
Operating lease liability	6	6	7	8	7
Total current liabilities	55	47	33	36	64
Long-term portion of operating lease liability	4	9	4	12	20
Long-term debt	100	50	49	50	48
Total liabilities	159	106	86	98	132
Commitments and contingencies (Note 13)	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.001 par value; 300,000,000 shares authorized; 108,461,354 and 93,823,678 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	108,000	94,000	76,000	52,000	35,000
Additional paid-in capital	1,546	1,291	901	772	548
Accumulated other comprehensive income	94,000	160,000	92,000	−884,000	−35,000
Accumulated deficit	−1,301	−923	−676	−511	−376
Total stockholders' equity	245	369	225	260	172
Total liabilities and stockholders' equity	404	475	311	358	304

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−378	−246	−166	−135	−132
Depreciation and amortization	2	2	3	3	3
Amortization of debt discount and debt issuance costs	423,000	253,000	274,000	720,000	335,000
Equity-based compensation	76	37	27	28	23
Amortization (accretion) of investment securities	−4	−5	−6	−2	918,000
Non-cash operating lease expense	5	5	7	7	6
Prepaid expenses and other current assets	−4	−6	5	−322,000	−9
Other assets	−286,000	1	−3	−97,000	−601,000
Accounts payable	208,000	7	−529,000	−251,000	1
Accrued expenses	8	11	−4	7	4
Operating lease liabilities	−6	−6	−8	−7	−5
Net cash used in operating activities	−300	−201	−145	−133	−127
Purchases of property and equipment	−602,000	−98,000	−71,000	−1	−5
Purchases of marketable securities	−98	−293	−291	−301	−60
Sales and maturities of marketable securities	317	217	332	130	200
Net cash provided by (used in) investing activities	219	−76	41	−172	134
Proceeds from stock option exercises	24	19	1	492,000	7
Proceeds from pre-funded and common warrant exercises	64	10	3	—	—
Proceeds from sale of common shares and pre-funded warrants to purchase common shares, net	92	324	98	195	13
Proceeds from debt facility	50	—	—	—	25
Debt modification payment	—	−125,000	—	−975,000	—
Proceeds from debt refinancing	25	—	—	—	—
Payment of long-term debt	−26	—	—	—	—
Net cash provided by financing activities	228	353	103	195	45
Net increase in cash, cash equivalents and restricted cash	147	76	—	—	—
Effect of exchange rate on cash, cash equivalents and restricted cash	−2,000	—	—	—	—
Operating lease liability adjustment from rent modification	—	9	—	—	—
Offering costs in accrued expenses	—	314,000	—	—	—
Cash paid for interest	6	7	6	4	2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro